文章：

光化性角化病与区域癌变局部免疫疗法

Topical Immunotherapy for Actinic Keratosis and Field Cancerization

原文发布日期：12 March 2024

DOI: 10.3390/cancers16061133

类型: Article

开放获取: 是

英文摘要：

This comprehensive review delves into various immunotherapeutic approaches for the management of actinic keratoses (AKs), precancerous skin lesions associated with UV exposure. Although there are treatments whose main mechanism of action is immune modulation, such as imiquimod or diclofenac, other treatments, apart from their main effect on dysplastic cells, exert some immunological action, which in the end contributes to their efficacy. While treatments like 5-fluorouracil, imiquimod, photodynamic therapy, and nicotinamide are promising in the management of AKs, especially in immunocompetent individuals, their efficacy is somewhat reduced in solid organ transplant recipients due to immunosuppression. The analysis extends to optimal combination, focusing on cryoimmunotherapy as the most relevant. New immunotherapies include resimiquimod, ingenol disoxate, N-phosphonacetyl-L-aspartate (PALA), or anti-PD1 that have shown promising results, although more studies are needed in order to standardize their use.

摘要翻译： 

本综述深入探讨了光化性角化病（一种与紫外线暴露相关的皮肤癌前病变）的多种免疫治疗方法。尽管存在以免疫调节为主要作用机制的治疗方法，如咪喹莫特或双氯芬酸，但其他疗法除对异型增生细胞产生主要作用外，亦发挥一定的免疫效应，最终共同提升疗效。虽然5-氟尿嘧啶、咪喹莫特、光动力疗法和烟酰胺等治疗手段在光化性角化病的治疗中展现出前景（尤其在免疫功能正常的个体中），但对于因免疫抑制状态导致疗效受限的实体器官移植受者，其治疗效果有所降低。本文进一步分析了优化联合治疗策略，重点关注最具相关性的冷冻免疫疗法。新型免疫疗法包括瑞西莫特、巨大戟醇二恶烷酯、N-膦酰乙酰-L-天冬氨酸及抗PD1药物等已显示出积极疗效，但其临床应用标准化仍需更多研究支持。

原文链接：

Topical Immunotherapy for Actinic Keratosis and Field Cancerization